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Background
Hemophilia A and B are disorders resulting from a defi-
ciency in factor VIII (FVIII), and factor IX (FIX), respec-
tively. Tissue Factor (TF) is a key component of the
extrinsic pathway and plays a role in the coagulation
defect of hemophilic blood. Neutralizing the activity of
TFPI represents a promising treatment concept in
patients with hereditary or acquired hemophilia.
ARC19499 is a polyethylene glycol (PEG)-conjugated
aptamer that binds to TFPI and inhibits its function as a
negative regulator of coagulation.
Methods
We evaluated the effect of the anti-TFPI aptamer
ARC19499 on thrombin generation and clot formation
in 40 hemophilia patients (congenital hemophilia:
29 adults, 10 children, one acquired hemophilia patient)
and 27 healthy male controls. Concentration-effect
curves of ARC19499 were assessed by the calibrated
automated thrombogram (CAT) and rotational throm-
belastometry (ROTEM) with and without corn trypsin
inhibitor (CTI) in whole blood and platelet-poor plasma.
Results
Clotting patterns were significantly compromised in
patients vs. controls. Measured FVIII:C levels in hemo-
philiacs correlated with parameters of the CAT assay
(except lag time) and also with the clotting time
assessed by ROTEM. ARC19499 had a concentration-
dependent pro-hemostatic effect in CAT and ROTEM.
ROTEM results with and without CTI were consistent.
ARC19499 normalized ROTEM clotting parameters and
rendered CAT patterns of hemophilia patients practi-
cally indistinguishable from those of controls. In
patients, ARC19499 normalized the endogenous throm-
bin potential, time-to-peak and the start tail, and
increased peak thrombin more than 2-fold. ARC19499
raised peak thrombin in patients with FVIII:C under 1%
to levels within the range of healthy controls and higher
than baseline in patients with FVIII:C above 5%. Effec-
tive concentrations of ARC19499 started at 2 nM. In an
acquired hemophilia patient ARC19499 worked
synergistically with activated prothrombin-complex con-
centrate/factor VIII inhibitor bypass activity (FEIBA)
pre-treatment. Similarly, in blood spiked with a FVIII
antibody, simulating a state of acquired hemophilia,
ARC19499 restored normal coagulation.
Conclusions
The anti-TFPI aptamer ARC19499 effectively enhanced
coagulation in blood of patients with congenital
or acquired hemophilia and therefore deserves further
evaluation in clinical trials.
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